Enrollment In Argos Therapeutics' Pivotal Phase III ADAPT Trial of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.